Plain-English translation of NCT05482893 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer medication called to see if it is safe and effective for people with advanced stomach, pancreatic, or bile duct cancers. The study will first test different doses of the medication alone, then test it combined with standard chemotherapy drugs or immunotherapy drugs that doctors already use. Researchers want to understand how well this treatment works and what side effects patients might experience.
These types of cancers are very difficult to treat and have limited treatment options. This medication is designed to target a specific protein on cancer cells, and early research suggests it might work better when combined with treatments doctors already use.
You likely qualify if…
You likely don't qualify if…
Depending on which part of the study you join, you will receive Spevatamig either alone or combined with standard chemotherapy or immunotherapy drugs through regular clinic visits. The study starts with a dose-escalation phase to find the safest dose, then moves to expansion phases testing the medication with various combinations of standard treatments. You will have blood tests, imaging scans, and health check-ins to monitor how you're responding and any side effects you experience.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States